AI in Medical Affairs: Emerging Platforms, Governance Challenges, and the Future of Scientific Engagement

Author(s): William Soliman

Artificial intelligence is rapidly transforming medical affairs from a primarily reactive support function into a proactive, intelligence-driven strategic capability. Across the pharmaceutical and biotechnology industries, medical affairs organizations are increasingly evaluating AI-powered platforms to support scientific exchange, medical information delivery, KOL engagement, congress intelligence, field insights analysis, and evidence dissemination.

But as AI adoption accelerates, the industry challenge is no longer simply identifying tools. The real challenge is determining which platforms can be deployed compliantly, responsibly, and effectively within the highly regulated environment of medical affairs.

As AI adoption accelerates across healthcare and life sciences, a broader industry conversation is emerging around AI governance, oversight, and accountability. While many organizations now offer AI education or implementation support, very few are focused specifically on establishing governance frameworks for AI use within medical affairs. This distinction is important. The future challenge for medical affairs organizations will not simply be identifying AI tools, but ensuring those tools are implemented responsibly, compliantly, and with appropriate scientific oversight. As a result, industry leaders are increasingly recognizing the need for standardized approaches to AI competency, governance evaluation, risk mitigation, and responsible deployment within regulated scientific environments. This is likely to become a defining area of focus for the next generation of medical affairs transformation.